Agios Pharmaceuticals Inc
|Number of Estimates|
Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
Market Cap: 3.4 Billion
Primary Exchange: NASDAQ/NMS (GLOBAL MARKET)
Shares Outstanding: 69.6 Million
Dividend: 0.0 (0.0%)
Industry: Pharmaceutical Preparation Manufacturing
Longest drawdown: 1594 trading days
From: 2015-01-14 To: 2021-03-02
Key events next week - healthcare
via: SeekingAlpha at 2019-06-13 03:28:10:000
Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more … read more...
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|